Access ESTRING materials to help
your patients and support your practice

Click below to receive the following items for your office:

ESTRING Savings Cards and Samples
Eligible patients pay no more than $15 for their next four ESTRING® (estradiol vaginal ring) prescriptions.
— Note: Includes ESTRING Demonstration Ring.
*Terms and Conditions apply

Click below to order or re-order the following items for your office:

ESTRING Patient Brochure
Use this patient brochure to help educate your patients about post-menopausal vaginal atrophy, and ESTRING.

ESTRING Patient Instructions Tear-pad
A tear pad to provide your patients instructions on how to insert and remove ESTRING.

ESTRING Demonstration Ring
Use this demonstration ring (containing no active ingredient) to show your patients the size, flexibility, and proper removal and insertion of ESTRING.

ESTRING Clinical Trifold Brochure
Learn more about the efficacy, safety, and overall patient acceptance of ESTRING with this brochure.

Indication

ESTRING is an estradiol vaginal ring indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus, and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria).

Important Safety Information

WARNINGS

ENDOMETRIAL CANCER
Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women's Health Initiative (WHI) estrogen alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women.

The estrogen plus progestin WHI substudy reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women.

The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI, reported increased risk of developing probable dementia in postmenopausal women aged 65 years or older. It is unknown whether this finding applies to younger postmenopausal women.

Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

ESTRING is contraindicated in women with the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast, uterus or other estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or a history of these conditions; active or recent (eg, within the past year) arterial thromboembolic disease (eg, stroke, myocardial infarction); known liver dysfunction or disease; or hypersensitivity to any of its ingredients. ESTRING should not be used in women with known or suspected pregnancy.

The most frequently reported adverse events associated with ESTRING were headache, leukorrhea, back pain, genital moniliasis, upper respiratory tract infection, and vaginal discomfort/pain/hemorrhage.

Please see full Prescribing Information, including Boxed Warning.

*Terms and Conditions

By using the ESTRING $15 Co-pay Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

  1. The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico [formerly known as "La Reforma De Salud"])
  2. The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs
  3. Patients must be 18 years or older
  4. By using the Card, patients will pay only $15 per prescription. Savings are limited to $100 for each of 4 uses
  5. You must deduct the value received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
  6. The Card cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription
  7. The Card will be accepted only at participating pharmacies
  8. The Card is not health insurance
  9. This offer is good only in the United States and Puerto Rico
  10. The Card is limited to one per person during this offering period and is not transferable
  11. Pfizer reserves the right to rescind, revoke, or amend the Card without notice

Offer expires 12/31/2014.
No membership fees apply.
For help with the ESTRING $15 Co-pay Card,
call 1-800-631-1181, or write:
Pfizer Inc, 235 East 42nd Street, New York, NY 10017. www.pfizer.com

Please scroll for Important Safety Information and Indication

Important Safety Information

WARNINGS

ENDOMETRIAL CANCER
Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.

The Women's Health Initiative (WHI) estrogen alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women.

The estrogen plus progestin WHI substudy reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women.

The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI, reported increased risk of developing probable dementia in postmenopausal women aged 65 years or older. It is unknown whether this finding applies to younger postmenopausal women.

Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

ESTRING is contraindicated in women with the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast, uterus or other estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or a history of these conditions; active or recent (eg, within the past year) arterial thromboembolic disease (eg, stroke, myocardial infarction); known liver dysfunction or disease; or hypersensitivity to any of its ingredients. ESTRING should not be used in women with known or suspected pregnancy.

The most frequently reported adverse events associated with ESTRING were headache, leukorrhea, back pain, genital moniliasis, upper respiratory tract infection, and vaginal discomfort/pain/hemorrhage.

Indication

ESTRING is an estradiol vaginal ring indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus, and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria).